Inhibikase Therapeutics, a groundbreaking clinical-stage pharmaceutical company, is making significant strides in the field of Parkinson’s disease and related disorders. Their recent publication in the esteemed Journal of Parkinson’s Disease highlights the groundbreaking results of their Phase 1 clinical studies with risvodetinib. This potential disease-modifying therapy has shown tremendous promise in modifying the course of Parkinson’s disease and other related disorders, offering hope to millions of patients worldwide.
The publication
Comments